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Abstract
Background. Achondroplasia (ACH) represents the major 
cause of dwarfi sm and is due to mutations in the fi broblast 
growth factor receptor 3 (FGFR3) gene. The cellular mecha-
nisms involved in the reduced growth have been mainly 
described for in vitro or in vivo models, but few data have 
been obtained for humans.
Methods. Thirteen children with ACH were enrolled in the 
study; the presence of FGFR3 mutations was determined 
by restriction fragment length polymorphism analysis and 
sequencing, whereas protein expression in cartilage biopsy 
was assessed by immunohistochemistry.
Results. Chondrocytes in cartilage biopsies of ACH children 
were characterized by the presence of growth arrest mediated 
by STAT activation (both STAT1 and STAT5) and increased 
expression of p21 and cyclin D1, whereas no expression of 
either p53 or cyclin D3 could be detected. This mechanism 
was present in ACH children carrying the G380R mutation 
but also in a patient in whom no mutation could be detected 
in the entire coding region of the FGFR3 gene.
Conclusions. These data thus demonstrate the presence of a 
common fi nal mechanism involving p21 and possibly leading 
to a block in chondrocyte proliferation.
Introduction
Achondroplasia (ACH, MIM# 100800), a common 
autosomal dominant skeletal dysplasia characterized by 
short stature, has a frequency of 1 : 26 000 live births.1 
More than 90% of the cases are sporadic, and there is 
a strong correlation with advanced paternal age, par-
ticularly over 35 years, suggesting that de novo muta-
tions have mainly a paternal origin.2
Achondroplasia is part of a spectrum of disorders 
with variable clinical traits, including severe achondro-
plasia with developmental delay and acanthosis nigri-
cans (SADDAN) and thanatophoric dysplasia (TD).3–5 
These disorders are characterized, in most cases, by the 
presence of mutations in the coding region of fi broblast 
growth factor receptor 3 (FGFR3); in particular, a 
G380R transition within the transmembrane domain 
has been detected in most ACH patients,6 whereas 
mutations affecting codon 650 are able to cause severe 
skeletal dysplasias such as TDII (K650E) and SADDAN 
(K650M).7
Fibroblast growth factor (FGF) receptors are tyro-
sine kinases (RTKs), which play a pivotal role in medi-
ating growth, differentiation, and cell migration in 
various cell types.8 Binding of an extracellular ligand 
FGF leads to receptor dimerization and subsequent 
tyrosine phosphorylation,9 followed by activation of 
various signal transduction proteins and pathways, 
such as STAT1, STAT3, STAT5, ERK1, ERK2, MAPK, 
phospholipase C, protein kinase C, Src, phosphati-
dylinositol 3-kinase, and Akt.10–14
FGF signaling is one of the main pathways that 
control bone development,8 in particular bone size, as 
supported by the fi ndings observed in FGFR3 knock-
out (KO) mice, in which severe bone dysplasia with 
enhanced growth due to expansion of proliferating 
chondrocytes in the growth plate is detected,15,16 Activa-
tion of FGFR3 inhibits chondrocyte proliferation and 
differentiation, as was also reported in studies on mouse 
models17,18; this growth inhibition is mediated by phos-
phorylation of STAT1, which then translocates in the 
nucleus and activates the cell cycle inhibitor p21Waf1/
Cip1.10–12,19 FGFs can also control bone growth through 
activation of the MAPK–ERK1/2 pathway in chondro-
cytes, which affects longitudinal growth by regulating 
hypertrophic chondrocyte differentiation and matrix 
deposition.20 FGFR3 mutations, such as those detected 
in achondroplasia and in TD have been shown to trigger 
STAT(s) signaling, increase expression of p21 in mouse 
and human cartilage models,10,11 and activate the MAP 
kinase pathway.10 However, up to now, most of the 
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studies have been performed on mouse or in vitro 
culture models, with only one article on analyzing this 
pathway in human fetuses.11 Thus, validation of these 
fi ndings in the cartilage of children with achondroplasia 
is still lacking.
The aim of this study was to characterize the genetic 
defect and evaluate the morphology and expression of 
proteins involved in the cell cycle in cartilage biopsies 
of achondroplasic children undergoing surgery for limb 
elongation.
Methods
Patient selection
Thirteen children (three males, ten females) with a 
clinical diagnosis of achondroplasia followed at the 
Istituto Ortopedico Gaetano Pini (Milan, Italy) were 
enrolled in the study. All patients were admitted to the 
hospital to undergo a limb elongation surgical proce-
dure. As controls, we employed DNAs (n = 10) and 
biopsy specimens (n = 8) obtained from age-matched 
controls undergoing surgery for a malignant neoplasm. 
The surgical samples were obtained from patients with 
osteosarcoma affecting the long bones (tibia and femur) 
but not involving articular cartilage. All of these sub-
jects underwent chemotherapy before surgery accord-
ing to standard international protocols.
The patients and their families were informed that 
data from the study would be submitted for publication 
and gave their consent. The study protocol conforms to 
the ethical guidelines of the 1975 Declaration of Hel-
sinki as refl ected in a priori approval by the Ethics 
Committee of the Istituto Ortopedico Gaetano Pini.
DNA extraction and detection of the G380R mutation
Genomic DNA was extracted from peripheral blood 
leukocytes using the Wizard genomic DNA purifi cation 
kit (Promega, Madison, WI, USA), according to the 
manufacturer’s instructions. Initial screening for detec-
tion of the G308R mutation was performed using a 
modifi cation of the method described by Lanning and 
Brown.21 Briefl y, 200 ng of DNA was used as a template 
for a polymerase chain reaction (PCR) performed using 
specifi c primers21 (fi nal concentration 200 nM) in the 
presence of 1.5 mM MgCl2 , 200 mM each dNTP, and 2 
units of Taq polymerase (Red Taq; Sigma-Aldrich, 
Milan, Italy). Amplifi cation was performed, after initial 
heating to 94°C for 5 min, at 94°C for 2 min, at 65°C for 
1 min, and at 72°C for 1 min over 40 cycles in a Perkin 
Elmer (system 2700) thermocycler, with a fi nal exten-
sion of 7 min at 72°C. PCR amplifi cation products were 
then separated on a 2% agarose gel to verify the correct 
size of the product (132 bp) and digested with 10 units 
of BsrGI (New England Biolabs, Beverly, MA, USA) 
at 37°C overnight. Digestion products were separated 
on a 3% agarose gel, and in presence of the mutation 
we detected 112- and 20-bp fragments.
Sequencing the FGFR3
To detect mutations different from the G380R, we 
sequenced the entire coding region of the FGFR3 
(exons 2–18). DNA regions containing exons and 
intron–exon junctions were amplifi ed using the primers 
described by Wüchner et al.,22 but in the case of exon 
9 we also designed a new pair of primers (forward 
5′-CCTCTCCTCGTCTCTGCTCA-3′ and reverse 
5′-CCTCTGACTGGTGGCTGTTT-3′) for better eval-
uation of the intron–exon junctions. All additional 
primers were designed using the Oligo Explorer soft-
ware. Amplifi cations were performed as described 
above, using different annealing temperatures accord-
ing to the primer pairs (details available on request). 
PCR conditions for exon 9 using the newly designed 
primers were at 94°C for 5 min, at 94°C for 1 min, at 
60°C for 1 min, and at 72°C for 2 min over 35 cycles. 
Amplifi ed products were purifi ed using ion-exchange 
columns (Qiaquick; Qiagen, Milan, Italy), and sequenc-
ing was performed using the ABI Prism terminator 
cycle sequencing ready reaction kit on an ABI Prism 
3100 Avant DNA sequencer (PE; Applied Biosystems, 
Foster City, CA, USA). All exons were sequenced using 
forward and reverse primers; the obtained sequences 
were aligned and independently manually checked by 
two of the authors (S.D.B., D.B.). Exons 7, 9, and 10 
were sequenced twice, using as the template two differ-
ent blood samples obtained from the patient not carry-
ing the G380K mutation. Every sequence was compared 
with its corresponding reference sequence available in 
GeneBank (NM_000142.2 for FGFR3).
Biopsy processing and evaluation
Biopsy specimens were obtained from articular carti-
lage, fi xed in a 10% solution of paraformaldehyde in 
0.1 M phosphate-buffered saline (PBS) pH 7.4, and 
embedded in paraffi n. Sections were mounted on poly-
lysine- or silane-treated slides (Sigma, Milan, Italy) for 
hematoxylin and eosin (H&E) staining and immunohis-
tochemistry. The sites of the biopsies are reported in 
Table 1. For ethical reasons, only small biopsy speci-
mens could be obtained during surgery; thus, we could 
not perform a classic histomorphometric analysis with 
computerized evaluation of the images. To quantify the 
number of chondrocytes present in controls and ACH 
patients, the cells present in four independent 400× 
fi elds were counted for each specimen, and an average 
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for each subject was calculated. Possible differences 
between the groups was evaluated by Student’s t-test 
using SAS System Software (version 9.1) (SAS Insti-
tute, Cary, NC, USA).
Immunohistochemistry
Immunohistochemistry was performed on all the sub-
jects enrolled in the study. Briefl y, slides were pretreated 
with 3% H2O2 for 15 min to inhibit endogenous peroxi-
dase and with a blocking agent (Normal Reagent; 
Vector, Burlingame, CA, USA) for 30 min to prevent 
background staining. Unmasking of the antigens was 
performed by incubating tissue sections in 10 mM 
sodium citrate buffer pH 6 for 9 min. Incubation with 
primary antibodies was performed for 1 h at room 
temperature using the following antibodies: anti-S100 
(1 : 200; Dako, Glostrup, Denmark), anti-STAT1 (1 : 200, 
Cell Signaling, Danvers, MA, USA), anti-STAT5 
(1 : 200, Cell Signaling), anti-p21 (1 : 100, Cell Signaling), 
anti-p53 (1 : 125; Dako), anti-cyclin D1 (1 : 200, Cell Sig-
naling), and anti-cyclin D3 (1 : 100, Cell Signaling). 
Detection of the hybridization signal was performed 
with biotinylated secondary antibodies [anti-rabbit 
immunoglobulin (IgG) or anti-mouse IgG] (Vector 
Elite Kit; Vector Laboratories, Burlingame, CA, USA), 
followed by peroxidase-conjugated streptavidin and 
diaminobenzidine solution (ABC detection system, 
Vector). Counterstaining was performed with Harris 
hematoxylin. Sections were examined independently by 
two pathologists (A P and EA) unaware of patients’ 
genotype.
Results
Patients’ clinical and radiological characteristics
The clinical features of the 13 achondroplasic children 
are reported in Table 1. All patients showed a decreased 
bone growth, with a stature below the 3rd percentile, 
with a weight that was below the 10th percentile. As 
reported in Table 2, all patients showed clinical signs 
typical of achondroplasia, such as macrocephaly, rhizo-
melic shortening of all the limbs, frontal bossing, mid-
face hypoplasia, and nasal bridge depression. Lower 
limb deformity was present in most patients, whereas 
other manifestations, such as trident hand, were rarer. 
As also described in Table 2, radiological signs of achon-
droplasia were detected in various percentages in all 
patients.
Genetic analysis of the FGFR3
We performed an initial screening to identify the pres-
ence of the G380R mutation in ACH patients using T
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S-100 expression was detected in the only patient with 
wild-type FGFR3 sequence when compared to controls 
or other achondroplasic patients (data not shown).
Immunohistochemical evaluation of cell cycle proteins
To assess whether the presence of a G380R was associ-
ated with an activation of the FGFR3 pathway. we 
evaluated the expression of STAT1, a transcription 
factor that has been identifi ed as one of the main regula-
tors of bone growth. As shown in Fig. 2A, STAT1 
expression was barely detectable in chondrocytes of 
controls subjects, whereas its expression was strongly 
augmented in biopsies of ACH patients, with increased 
staining in the nuclear region, compatible with nuclear 
translocation of the transcription factor (Fig. 2B). Inter-
estingly, even in the absence of FGFR3 mutations, a 
signal for STAT1 could be detected, although possibly 
not as strong as that detected in G380R patients (Fig. 
2C). We also evaluated STAT5 expression, which was 
almost absent in controls; it was increased in patients 
with the G380R mutation (Fig. 3A,B). Unfortunately, 
in the patient with no FGFR3 mutations, immunohisto-
chemistry using the anti-STAT5 antibody did not give 
consistent results (data not shown). To block cell cycle 
progression, STAT1 acts on p21; thus, we evaluated p21 
expression, which was not detectable in control biopsies 
(Fig. 4A) but was strongly expressed in chondrocytes of 
achondroplasic patients independently from the pres-
ence or absence of the G380R mutation (Fig. 4B,C). 
The p21 expression can also be regulated by p53 and 
for this reason we evaluated, by immunohistochemistry, 
whether p53 protein was up-regulated in subjects 
with achondroplasia. This analysis did not reveal any 
Table 2. Patients’ clinical and radiological signs
Signs 1 2 3 4 5 6 7 8 9 10 11 12 13
Clinical signs
 Macrocephaly + + + + + + + + + + + + +
 Frontal bossing + + + + + + + + + + + + +
 Midface hypoplasia + + + + + + + + + + + + +
 Nasal bridge depression + + + + + + + + + + + + +
 Rhizomelic shortening of all limbs + + + + + + + + + + + + +
 “Trident” hand + + + − + + − − + − − − −
 Elbow contracting during bending + + + + + + − + + + + + +
 Thoracolumbar gibbus + + + − + + + + − − − + +
 Vertebral canal stenosis − − − − − − − − − − − − −
 Lower limbs deformity + − + + + + − + + + + + +
Radiological signs
 Interpedicular distance decrease + + − + + + + + + + + + −
 Pelvic diameter increase + + + + + + + + + − − − +
 Calf bone longer than shinbone − − + + − + + + + − − + +
 Rhizomelic shortening of all the limbs + + + + + + + + + + + + +
 Vertebral column deformity + + + − + + + + − + + + +
 Lower limb deformity + − + + + + − + + + + + +
restriction enzyme digestion of the amplifi ed DNA 
region harboring the mutation. Among the 13 analyzed 
patients, 12 carried the G380R mutation in heterozygo-
sis, as demonstrated by the presence of the uncut (wild-
type) and cut (mutated) alleles on gel electrophoresis 
(data not shown). In one patient 13, the mutation was 
not detected; we fi rst sequenced the amplifi ed product 
to confi rm the lack of mutation and then performed an 
analysis of the entire coding region to assess whether 
other mutations were present in the exons codifying for 
the extracellular, transmembrane, or cytoplasmic region 
of the FGFR3 protein. Although exons 2–18 and intron/
exon junctions were sequenced in both forward and 
reverse, we could not detect any mutation.
Morphological evaluation of cartilage biopsies
Cartilage biopsy specimens obtained during surgery 
were fi rst analyzed using standard histology techniques 
(Fig. 1). Compared to cartilage obtained from age-
matched controls with normal growth, the samples from 
achondroplasic patients showed a reduced number of 
chondrocytes, with shortening of normal column place-
ment and of transitional calcifi cation areas (Fig. 1C,D). 
The average number of chondrocytes, as determined in 
a 400× fi eld, was 21.75 ± 2.55 in control samples com-
pared to 16.35 ± 2.34 in ACH biopsies (P < 0.05). A 
similar pattern was observed even in the subject who 
was negative for mutations in the FGFR3 gene (data 
not shown).
S-100 expression was assessed by immunohistochem-
istry, and similar levels of expression were observed in 
chondrocytes in control subjects and G380R mutated 
patients (data not shown). No signifi cant difference in 
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signifi cant difference between controls and ACH 
patients, showing a very low level (almost undetectable) 
of expression of p53 (data not shown). Up-regulation of 
p21 suggests arrest of cell cycle progression; thus, we 
analyzed the expression of two cyclin D subtypes, 
which are essential in the G1-S phase transition. Cyclin 
D1 expression was not detectable in control biopsies, 
whereas intense positive staining was present in 
all ACH patients, with or without FGFR3 mutations 
(Fig. 5).
As regards cyclin D3, no immunostaining signal could 
be identifi ed either in controls or in ACH patients, sug-
gesting the lack of accumulation of this protein in the 
analyzed chondrocytes (data not shown).
Fig. 1. Morphological evaluation of cartilage biopsy speci-
mens. A Control epiphyseal cartilage (×400). B Control transi-
tion cartilage (×200). C Achondroplasic epiphyseal cartilage 
(patient with G380R mutation) (×400). D Achondroplasic 
transition cartilage (patient with G380R mutation) showing a 
reduced number of chondrocytes (×200)
Fig. 2. Immunohistochemistry analysis of STAT1 expression. 
A Control epiphyseal cartilage with no signal. B Achondro-
plasic epiphyseal cartilage (patient with G380R mutation) 
shows increased STAT1 expression. C Achondroplasic epiph-
yseal cartilage (patient without G380R mutation). (A–C 
×400)
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Discussion
Achondroplasia represents one of the most common 
forms of dwarfi sm and is generally due to mutations in 
the FGFR3 gene. Several studies performed with in 
vitro and in vivo models have provided, during the last 
few years, insights regarding the pathogenetic mecha-
nisms responsible for premature bone growth arrest. 
However, few studies have been performed on human 
samples. Here we describe the morphological and 
expression analysis of cartilage samples obtained from 
achondroplasic children, showing activation of the 
STAT pathway and detecting similar fi ndings in patients 
with the G380R mutation and in one subject with no 
mutation detected in the entire coding region.
Achondroplasia is due, in most of the patients, to a 
point mutation causing an amino acid change (G380R) 
in the transmembrane domain of FGFR3, resulting in a 
Fig. 3. Immunohistochemistry analysis of STAT5 expression. A Control epiphyseal cartilage with no detectable STAT5 expres-
sion. B Achondroplasic epiphyseal cartilage (patient with G380R mutation) shows increased STAT5 expression. (A, B ×400)
Fig. 4. Immunohistochemistry evaluation of p21 expression. 
A Control epiphyseal cartilage with no signal. B Achondro-
plasic epiphyseal cartilage (patient with G380R mutation) 
shows increased p21 expression. C Achondroplasic epiphyseal 
cartilage (patient without G380R mutation) with increased 
p21 expression. (A–C ×400)
Fig. 5. Immunohistochemistry analysis of cyclin D1 expres-
sion. A Control epiphyseal cartilage with no signal. B Achon-
droplasic epiphyseal cartilage (patient with G380R mutation). 
C Achondroplasic epiphyseal cartilage (patient without 
G380R mutation). (A–C ×400)
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gain of function and consequent activation of the down-
stream signaling cascade involving either STAT1 or the 
MAPK–ERK pathway.10–12 Among the 13 children ana-
lyzed here, 12 were carriers of the G380R mutation; the 
remaining child did not show any mutation in the 
FGFR3 gene, although the clinical characteristics and 
the clinical and radiological signs were identical to those 
observed in the other 12 patients. The sequencing of the 
entire coding region of the FGFR3 gene did not reveal 
the presence of mutations in the examined exons. The 
G380R mutation is detected in about 98% of ACH 
patients, although other, rarer mutations have been 
reported, such as Gly375Cys.23 A more recent article, 
Heuertz et al.24 reported a patient with ACH who 
carried a single base substitution converting serine 279 
into cysteine (S279C) in the third Ig loop of the extra-
cellular portion of the receptor another mutation in 
the same proteic region was associated with a more 
severe phenotype in hypochondroplasia. This mutation, 
reported also by Friez and Wilson,25 is localized in 
exon 7. Both studies suggested that sequencing of this 
exon be included in the screening for ACH and HCH. 
Another study on 24 Portuguese patients with ACH 
fi rst sequenced exons 9 and 10, identifying the G380R 
mutation in 21 cases, a N540K substitution in two, and 
no mutation after sequencing of the entire gene in one 
subject.26 Although no mutation was detected in our 
patient, we could not exclude the possibility that varia-
tions at the transcriptional or posttranscriptional level 
could alter FGFR3 expression in the affected tissue (i.
e., the cartilage); however, the amount of tissue obtained 
prevented us from performing these analyses.
STAT1 immunohistochemistry evaluation revealed 
the presence of the activated transcription factor in the 
cytoplasm as well as the nucleus of chondrocytes of 
patients with reduced bone growth, and in this case, 
independently from the presence of the G380R muta-
tion. These fi ndings are in agreement with those 
reported by Legeai-Mallet et al., who identifi ed the 
same alteration in fetuses affected by ACH or TD.11 
Hyperactivation of STAT1 thus remains through differ-
ent ages, showing that FGFR3 pathway activation is 
present not only in fetuses but in young children. STAT1 
activation is commonly regarded as able to block cell 
cycle progression through the induction of p21,12,16 
although there may be some exceptions, as reported by 
Nowroozi et al.27 who, in a cellular model of thanato-
phoric dysplasia, showed that siRNA-induced STAT1 
down-regulation was unable to affect p21 expression. In 
all of the examined ACH biopsies in our study, p21 
expression was strongly increased compared to that of 
the control samples; interestingly, p21 hyperexpression 
was also detected in the patient with no FGFR3 muta-
tion, suggesting that the mechanism leading to cessation 
of cell division uses a common fi nal pathway. Increased 
expression of p21 has been previously reported in 
animal and cellular models of achondroplasia.10,12 Our 
fi ndings in humans agree with those observed in the 
cartilage of fetuses affected by ACH or TD.11 However, 
p21 could block the cell cycle as a response to different 
stimuli, and its expression could be also regulated by 
p53, which is activated in the presence of cellular damage 
(mostly DNA damage) and induces p21 transcription.28 
We could not detect any increased expression or nuclear 
transmigration of p53 in the chondrocytes of the ana-
lyzed ACH patients, which supports the hypothesis that 
p21 hyperexpression is due to a primary alteration 
causing ACH.
The effect of p21 on the cell cycle is mediated by a 
block of the D cyclin–CDK4 complex, which is essential 
for progression from the G1 to the S phase of growth.
28 
Although this block is usually associated with a reduc-
tion in D cyclin protein levels,29,30 it has also been 
reported that p21 can bind to the D cyclin–CDK4 
complex and prevent it from functioning without induc-
ing any signifi cant alteration in the protein level of the 
components of the complex.28 We observed increased 
expression of cyclin D1 in the ACH cartilage biopsies 
analyzed in this study, whereas cyclin D3 was not detect-
able. The cyclin D1 fi ndings are thus in agreement with 
the possibility that p21 stabilizes the cyclin–CDK 
complex rather than inducing its degradation.
Conclusion
This study provides evidence regarding activation of the 
STAT pathway even in biopsies of achondroplasic chil-
dren and that p21 hyperexpression may represent the 
fi nal effector mechanism causing cell cycle arrest even 
in the absence of detectable FGFR3 mutation.
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